Turpie A G
McMaster University, Hamilton, Ontario, Canada.
Cardiol Clin. 1994 Aug;12(3):487-93.
Despite improvements in valve design, thromboembolic complications remain an important complication in patients with heart valve replacement. Less intense anticoagulant regimens with or without concomitant antiplatelet therapy have been shown to be effective and safe in such patients. The recommended intensity of oral anticoagulants for tissue valves is an INR of 2.0 to 3.0 and 2.5 to 3.5 for mechanical valves.
尽管瓣膜设计有所改进,但血栓栓塞并发症仍是心脏瓣膜置换患者的重要并发症。在这类患者中,采用或不采用联合抗血小板治疗的强度较低的抗凝方案已被证明是有效且安全的。对于生物瓣膜,口服抗凝剂的推荐强度是国际标准化比值(INR)为2.0至3.0;对于机械瓣膜,INR为2.5至3.5。